Fennec Pharmaceuticals (FENC) Cash from Operations Growth (3y) (2013 - 2025)
Fennec Pharmaceuticals (FENC) Cash from Operations Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 34.32% |
| 10 | Fennec Pharmaceuticals | 292.06 Mn | 255.27 Mn | 12.01 Mn | 4.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.30% |
| Sep 30, 2025 | 31.96% |
| Jun 30, 2025 | -2.83% |
| Mar 31, 2025 | -14.77% |
| Dec 31, 2024 | 23.13% |
| Sep 30, 2024 | 9.31% |
| Jun 30, 2024 | -23.75% |
| Mar 31, 2024 | 134.33% |
| Dec 31, 2023 | -13.96% |
| Sep 30, 2023 | 20.27% |
| Jun 30, 2023 | -8.19% |
| Mar 31, 2023 | -14.16% |
| Dec 31, 2022 | -62.34% |
| Sep 30, 2022 | -30.87% |
| Jun 30, 2022 | -7.15% |
| Mar 31, 2022 | -4.83% |
| Dec 31, 2021 | -3.46% |
| Sep 30, 2021 | -22.76% |
| Jun 30, 2021 | -41.27% |
| Mar 31, 2021 | -27.66% |